MA31447B1 - Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 - Google Patents

Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1

Info

Publication number
MA31447B1
MA31447B1 MA32421A MA32421A MA31447B1 MA 31447 B1 MA31447 B1 MA 31447B1 MA 32421 A MA32421 A MA 32421A MA 32421 A MA32421 A MA 32421A MA 31447 B1 MA31447 B1 MA 31447B1
Authority
MA
Morocco
Prior art keywords
dicarboxylic acid
acid derivatives
receptor agonists
novel dicarboxylic
compounds
Prior art date
Application number
MA32421A
Other languages
English (en)
Inventor
Marc Capet
Nicolas Levoin
Isabelle Berrebi-Bertrand
Philippe Robert
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Jayraj Dilipbhai Aradhye
Muthukumaran Natarajan Pillai
Bhavesh Mohanbhai Panchal
Jignesh Kantilal Jivani
Biswajit Samanta
Ranjan Kumar Pal
Rajamannar Thennati
Original Assignee
Bioprojet Soc Civ
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ, Sun Pharma Advanced Res Co Ltd filed Critical Bioprojet Soc Civ
Publication of MA31447B1 publication Critical patent/MA31447B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS REPRÉSENTÉS PAR LA FORMULE GÉNÉRALE (I) EXERÇANT UNE ACTIVITÉ AGONISTE CONTRE LES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE (S1P), LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION COMME AGENTS IMMUNOSUPPRESSEURS. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS ET L'UTILISATION DE CES COMPOSÉS POUR LE TRAITEMENT/LA PRÉVENTION DE MALADIES ET DE TROUBLES INDUITS PAR LE SYSTÈME IMMUNITAIRE OU DE MALADIES ET DE TROUBLES INFLAMMATOIRES.
MA32421A 2007-06-15 2009-12-15 Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 MA31447B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290748A EP2014653A1 (fr) 2007-06-15 2007-06-15 Nouveaux dérivés d'acide dicarboxylique comme agonistes du recepteur S1P1

Publications (1)

Publication Number Publication Date
MA31447B1 true MA31447B1 (fr) 2010-06-01

Family

ID=38645817

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32421A MA31447B1 (fr) 2007-06-15 2009-12-15 Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1

Country Status (17)

Country Link
US (1) US8809539B2 (fr)
EP (2) EP2014653A1 (fr)
JP (1) JP5346016B2 (fr)
KR (1) KR20100040853A (fr)
CN (1) CN101784535A (fr)
BR (1) BRPI0811712A2 (fr)
CA (1) CA2693126A1 (fr)
CO (1) CO6251262A2 (fr)
EA (1) EA018826B1 (fr)
IL (1) IL202741A0 (fr)
MA (1) MA31447B1 (fr)
MX (1) MX2009013733A (fr)
NZ (1) NZ581933A (fr)
TN (1) TN2009000524A1 (fr)
UA (1) UA99132C2 (fr)
WO (1) WO2008152149A1 (fr)
ZA (1) ZA200908851B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970420B (zh) * 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物
US8404676B2 (en) 2007-10-04 2013-03-26 Merck Serono Sa Oxadiazole diaryl compounds
WO2009060278A1 (fr) * 2007-11-08 2009-05-14 Pfizer Inc. Dérivés d'acide cyclobutylcarboxylique
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
PL2342205T4 (pl) 2008-08-27 2016-12-30 Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
CA2739901A1 (fr) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd Modulateurs des recepteurs s1p
CN102186845B (zh) 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
EP2241558A1 (fr) * 2009-04-03 2010-10-20 Merck Serono SA Dérivés d'oxadiazole
WO2011048409A1 (fr) 2009-10-20 2011-04-28 Astrazeneca Ab Dérivés d'amine cyclique ayant une activité agoniste de récepteur adrénergique bêta-2 et antagoniste de récepteur muscarinique
EP2528894A1 (fr) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
JP5735634B2 (ja) * 2010-04-23 2015-06-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
ES2515415T3 (es) * 2010-04-27 2014-10-29 Allergan, Inc. Derivados de 3-(4-((1H-imidazol-1-il)metil)fenil)-5-aril-1,2,4-oxadiazol como moduladores de receptores de la esfingosina-1-fosfato
WO2012009649A1 (fr) * 2010-07-16 2012-01-19 Anderson Gaweco Inhibiteurs mif et leurs utilisations
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換３−フェニル−１，２，４−オキサジアゾール化合物
WO2012112841A2 (fr) * 2011-02-18 2012-08-23 Abbott Laboratories Préparation de sels d'acide [1,2,4]oxadiazol-3-yl]-ylique et formes cristallines et leur préparation
EP2511275A1 (fr) 2011-04-12 2012-10-17 Bioprojet Nouveaux acides pipéridiniles monocarboxyliques comme agonistes du récepteur S1P1
CA3002540C (fr) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Utilisation de (r)-2-(7-(4-cyclopentyl-3(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acide acetique pour le traitement de conditions liees au recepteur s1p1
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
WO2018119080A1 (fr) * 2016-12-21 2018-06-28 Cornell University Composition et méthodes de traitement de troubles hépatiques
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用
MX2020007948A (es) 2018-02-02 2020-12-10 Univ Kyoto Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
EP3847158B1 (fr) 2018-09-06 2026-06-24 Arena Pharmaceuticals, Inc. Composés utiles dans le traitement des troubles auto-immuns et inflammatoires
CN111803636B (zh) * 2020-07-22 2022-08-30 四川大学 1-磷酸鞘氨醇受体1作为microRNA-9调控血管生成的药物靶点的应用
US20240228441A1 (en) * 2021-04-14 2024-07-11 Lg Chem, Ltd. Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist
RU2765464C1 (ru) * 2021-05-20 2022-01-31 Федеральное государственное бюджетное учреждение науки Институт органической химии им. Н.Д. Зеленского Российской академии наук (ИОХ РАН) Способ получения эфиров пиперидин-4,4-дикарбоновых кислот
JP7464075B2 (ja) 2022-04-20 2024-04-09 株式会社大林組 プレストレス構造及びそれを用いたプレキャストコンクリート部材

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549640A4 (fr) * 2002-06-17 2008-08-06 Merck & Co Inc 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg
AU2003279915A1 (en) * 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
ATE496024T1 (de) * 2002-12-20 2011-02-15 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
ES2308127T3 (es) * 2004-10-22 2008-12-01 Bioprojet Nuevos derivados de acidos dicarboxilicos.

Also Published As

Publication number Publication date
BRPI0811712A2 (pt) 2014-11-04
EP2014653A1 (fr) 2009-01-14
EP2170850A1 (fr) 2010-04-07
TN2009000524A1 (en) 2011-03-31
US20100249187A1 (en) 2010-09-30
JP2010529977A (ja) 2010-09-02
WO2008152149A1 (fr) 2008-12-18
CN101784535A (zh) 2010-07-21
EA018826B1 (ru) 2013-11-29
IL202741A0 (en) 2010-06-30
NZ581933A (en) 2012-01-12
JP5346016B2 (ja) 2013-11-20
UA99132C2 (ru) 2012-07-25
EA201000024A1 (ru) 2010-06-30
EP2170850B1 (fr) 2014-09-24
KR20100040853A (ko) 2010-04-21
CO6251262A2 (es) 2011-02-21
AU2008263817A1 (en) 2008-12-18
CA2693126A1 (fr) 2008-12-18
US8809539B2 (en) 2014-08-19
MX2009013733A (es) 2010-04-22
ZA200908851B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MX2009013733A (es) Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1.
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
TN2013000349A1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30289B1 (fr) Dérivés d'amines
TN2009000028A1 (fr) Agonistes de ep2
MA30639B1 (fr) Composes chimiques.
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
TN2009000138A1 (fr) Biaryl-ether-urees
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA32120B1 (fr) Nouveaux composes chimiques
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA34308B1 (fr) Triazolopyridines substituées
MA35444B1 (fr) Ligands du récepteur ep1